血管新生因子与酶在多发性骨髓瘤不同临床阶段中的变化  

Changes of Angiogenic Factors in Different Clinical Stages of Multiple Myeloma

作　　者：杨光忠[1] 陈文明[1] 刘晋玮[1] 

机构地区：[1]首都医科大学附属北京朝阳医院血液内科

出　　处：《首都医科大学学报》2007年第6期763-765,共3页Journal of Capital Medical University

基　　金：北京市科技新星计划基金项目部分资助(954812300)~~

摘　　要：目的比较多发性骨髓瘤(multiple myeloma,MM)患者不同临床阶段骨髓中血管新生因子与酶的水平,分析血管新生因子与酶在病情演变中的变化。方法选取66例MM患者和14例意义未明的单克隆免疫球蛋白病(MGUS)患者为研究对象。所有研究对象均进行骨髓穿刺。应用ABC-ELISA法测定骨髓中血管新生因子与酶(IL-6、VEGF、bFGF、MMP-2、MMP-9)的水平。结果新诊断MM患者与复发/难治MM患者的骨髓血管新生因子与酶水平无明显差异,均高于缓解患者与MGUS;MGUS患者除MMP-9低于缓解MM患者外,其余细胞因子与酶水平与缓解患者无明显差异。结论MM患者骨髓中血管新生因子与酶水平与其病情正相关,测定血管新生因子与酶的浓度可以用来评价患者的病情。Objective To analyze the changes of angiogenic factors during the development of MM in different clinical stages.Methods Sixty-six MM patients and 14 monoclonal gammopathy patients of undetermined significance（MGUS） were studied.Five-milliliter of bone marrow,anticoagulate with heparin,were obtained from each patient.The levels of angiogenic factors（IL-6,VEGF,bFGF,MMP-2,MMP-9） in BM were determined with ABC-ELISA.Results There was no difference in angiogenic factors between the newly diagnosed and refractory/relapsed MM,but they were higher than MM at remission and MGUS.There was no difference in angiogenic factors except for MMP-9 between MM at remission and MGUS.Conclusion The levels of angiogenic factors in bone marrow of MM patients are positively correlated with the patient＇s condition.Determinations of the concentrations of angiogenic factors are useful for the evaluation of the disease course.

关 键 词：多发性骨髓瘤 血管新生 血管新生因子 

分 类 号：R551.3[医药卫生—血液循环系统疾病]